Generer rapport
P/S Sunstone Biomedicinsk Venture III
Store Strandstræde 18A, st, 1255 København K, CVR 25884132
Virksomhedsform
Kommanditaktieselskab / Partnerselskab
Etableret
2001
Størrelse
Mikro
Ansatte
-
Omsætning
-
DKK
Bruttofortj.
-450.000
DKK
Primært resultat (EBIT)
-450.000
DKK
Årets resultat
-14.396.000
DKK
Egenkapital
73.000
DKK
Den viste virksomhed har en særlig status
Bemærk, at virksomheden er registreret med følgende status: Opløst efter frivilling likvidation (25-03-2021). annonce
Flere nøgletal og analyser?
Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!
Stamoplysninger baseret på CVR
| Navn | P/S Sunstone Biomedicinsk Venture III |
| Binavne | Bi Biomedical Venture III Ltd. P/S, Bi Biomedicinsk Venture III Ltd. P/S Vis mere |
| CVR | 25884132 |
| Adresse | Store Strandstræde 18A, st, 1255 København K |
| Branche | Ventureselskaber og kapitalfonde [643040] |
| Etableret/nedlagt | 30-01-2001 - 25-03-2021 (20 år) |
| Første regnskabsperiode | 30-01-2001 til 31-12-2001 |
| Virksomhedsform | Kommanditaktieselskab / Partnerselskab |
| Antal ansatte | - |
| Reklamebeskyttelse | Nej |
| Regnskabsperiode | 01-01 til 31-12 |
| Selskabskapital | 10.002.959 DKK 10.002.959 DKK (17-08-2005 - 25-03-2021) 1.186.709.376 DKK (25-04-2005 - 16-08-2005) 1.690.500.000 DKK (17-11-2004 - 24-04-2005) 1.437.000.000 DKK (29-04-2004 - 16-11-2004) 1.268.000.000 DKK (29-04-2003 - 28-04-2004) |
| Vedtægter seneste | 24-02-2015 |
Medlem af brancherne
- Ventureselskaber og kapitalfondeNACE6 indeholdende 502 virk.
- Investeringsforeninger, investeringsselskaber o.l.NACE3 indeholdende 8.703 virk.
- Pengeinstitut- og finansieringsvirksomhed undtagen forsikring og NACE2 indeholdende 149.107 virk.
- Pengeinstitut- og finansvirksomhed, forsikringNACE1 indeholdende 152.083 virk.
Regnskab
| 2019 | 2018 | 2017 | |
|---|---|---|---|
| Valuta/enhed | 000' DKK | 000' DKK | 000' DKK |
| Omsætning | - - | - - | - - |
| Bruttofortjeneste | -450 - | -822 - | -429 - |
| Årets resultat | -14.396 - | 3.067 +220% | 957 - |
| Egenkapital | 73 -100% | 18.302 -18% | 22.414 -10% |
| Balance | 97 -99% | 18.327 -18% | 22.436 -10% |
Ledelsesberetning
The Fund’s administration was taken over by Sunstone Capital A/S on 1 January 2010 followed by another transfer within Sunstone to Sunstone Life Science Ventures A/S on 1 May 2016.
The Fund was taken under voluntary liquidation with effect from 15 July 2016.
The result for the year showed a loss of DKK 14,396k influenced by realised and unrealised net loss on investments of DKK 13,943k.
Development in selected portfolio companies:
F2G Ltd: Located in Manchester, UK, is a drug development company focused on the development of novel agents to treat serious fungal diseases. F2G has obtained a EUR 24 million loan from European Investment Bank’s (EIB) InnovFin – Infectious Diseases Finance Facility’ (IDFF) run under Horizon 2020. This is expected to allow the company to complete clinical development and file for marketing authorization in 2023.
Santaris Pharma (acquired by Roche 2013): Sunstone is chairing the Sellers’ Committee whose sole purpose is to ensure the purchaser’s compliance with the Share Purchase Agreement signed in September 2013 between Purchaser Hoffman La Roche (Roche) and the 54 Sellers, among which Sunstone was the largest single shareholder. During 2019 the Fund received two minor milestone payments from Roche, which was distributed to the LP’s. Further milestone payments are very uncertain, but Sunstone is expecting final and last update from Roche in February 2020, when the agreement with Roche expires.
Zymenex Holding (asset acquired by Chiezi 2013): Zymenex' lead compound Lamzede (formerly "Lamazyme") for the treatment of the rare disease alpha-mannosidosis was evaluated by EMA in 2017 and subsequently was granted marketing authorization in 2018. The grant triggered a EUR 10 million milestone payment from Chiesi Pharmaceutici to Zymenex's former shareholders (distributed in 2018). Chiesi has now launched Lamzede in several European countries and has initiated price negotiations with the relevant authorities in these countries. To our knowledge none of the negotiations have been finalized, however, we can see that Lamzede is listed in several European countries at prices below the threshold that will trigger additional milestone payments to Zymenex’ shareholders.
The Fund was taken under voluntary liquidation with effect from 15 July 2016.
The result for the year showed a loss of DKK 14,396k influenced by realised and unrealised net loss on investments of DKK 13,943k.
Development in selected portfolio companies:
F2G Ltd: Located in Manchester, UK, is a drug development company focused on the development of novel agents to treat serious fungal diseases. F2G has obtained a EUR 24 million loan from European Investment Bank’s (EIB) InnovFin – Infectious Diseases Finance Facility’ (IDFF) run under Horizon 2020. This is expected to allow the company to complete clinical development and file for marketing authorization in 2023.
Santaris Pharma (acquired by Roche 2013): Sunstone is chairing the Sellers’ Committee whose sole purpose is to ensure the purchaser’s compliance with the Share Purchase Agreement signed in September 2013 between Purchaser Hoffman La Roche (Roche) and the 54 Sellers, among which Sunstone was the largest single shareholder. During 2019 the Fund received two minor milestone payments from Roche, which was distributed to the LP’s. Further milestone payments are very uncertain, but Sunstone is expecting final and last update from Roche in February 2020, when the agreement with Roche expires.
Zymenex Holding (asset acquired by Chiezi 2013): Zymenex' lead compound Lamzede (formerly "Lamazyme") for the treatment of the rare disease alpha-mannosidosis was evaluated by EMA in 2017 and subsequently was granted marketing authorization in 2018. The grant triggered a EUR 10 million milestone payment from Chiesi Pharmaceutici to Zymenex's former shareholders (distributed in 2018). Chiesi has now launched Lamzede in several European countries and has initiated price negotiations with the relevant authorities in these countries. To our knowledge none of the negotiations have been finalized, however, we can see that Lamzede is listed in several European countries at prices below the threshold that will trigger additional milestone payments to Zymenex’ shareholders.
28-02-2020